Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).Stomatitis: INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.Placebo Effect: An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.Mouth Mucosa: Lining of the ORAL CAVITY, including mucosa on the GUMS; the PALATE; the LIP; the CHEEK; floor of the mouth; and other structures. The mucosa is generally a nonkeratinized stratified squamous EPITHELIUM covering muscle, bone, or glands but can show varying degree of keratinization at specific locations.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Radiation Injuries: Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.Radiotherapy: The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Mouthwashes: Solutions for rinsing the mouth, possessing cleansing, germicidal, or palliative properties. (From Boucher's Clinical Dental Terminology, 4th ed)Fibroblast Growth Factor 7: A fibroblast growth factor that is a specific mitogen for EPITHELIAL CELLS. It binds a complex of HEPARAN SULFATE and FIBROBLAST GROWTH FACTOR RECEPTOR 2B.Cross-Over Studies: Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed)Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Antimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Xerostomia: Decreased salivary flow.Leucovorin: The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.Laser Therapy, Low-Level: Treatment using irradiation with LASER light of low power intensity so that the effects are not due to heat, as they are in LASER THERAPY.Glossitis: Inflammation of the tongue.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Oral Ulcer: A loss of mucous substance of the mouth showing local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue. It is the result of a variety of causes, e.g., denture irritation, aphthous stomatitis (STOMATITIS, APHTHOUS); NOMA; necrotizing gingivitis (GINGIVITIS, NECROTIZING ULCERATIVE); TOOTHBRUSHING; and various irritants. (From Jablonski, Dictionary of Dentistry, 1992, p842)Benzydamine: A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.Ageusia: Complete or severe loss of the subjective sense of taste, frequently accompanied by OLFACTION DISORDERS.Drug Evaluation: Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Lichenoid Eruptions: Conditions in which there is histological damage to the lower epidermis along with a grouped chronic inflammatory infiltrate in the papillary dermis disturbing the interface between the epidermis and dermis. LICHEN PLANUS is the prototype of all lichenoid eruptions. (From Rook et al., Textbook of Dermatology, 4th ed, p398)Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).Oral Hemorrhage: Bleeding from the blood vessels of the mouth, which may occur as a result of injuries to the mouth, accidents in oral surgery, or diseases of the gums.Eriobotrya: A plant genus of the family ROSACEAE that is the source of an edible fruit. Members contain TRITERPENES.Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Radiation-Protective Agents: Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other, e.g. military, purposes.Radiodermatitis: A cutaneous inflammatory reaction occurring as a result of exposure to ionizing radiation.SucraseProspective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Tolonium Chloride: A phenothiazine that has been used as a hemostatic, a biological stain, and a dye for wool and silk. Tolonium chloride has also been used as a diagnostic aid for oral and gastric neoplasms and in the identification of the parathyroid gland in thyroid surgery.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Anti-Infective Agents, Local: Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects.Hematologic Diseases: Disorders of the blood and blood forming tissues.Pilot Projects: Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Hematoxylin: A dye obtained from the heartwood of logwood (Haematoxylon campechianum Linn., Leguminosae) used as a stain in microscopy and in the manufacture of ink.Lasers, Semiconductor: Lasers with a semiconductor diode as the active medium. Diode lasers transform electric energy to light using the same principle as a light-emitting diode (LED), but with internal reflection capability, thus forming a resonator where a stimulated light can reflect back and forth, allowing only a certain wavelength to be emitted. The emission of a given device is determined by the active compound used (e.g., gallium arsenide crystals doped with aluminum or indium). Typical wavelengths are 810, 1,060 and 1,300 nm. (From UMDNS, 2005)Cryotherapy: A form of therapy consisting in the local or general use of cold. The selective destruction of tissue by extreme cold or freezing is CRYOSURGERY. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Intestinal Mucosa: Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI.Severity of Illness Index: Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.Intestine, Small: The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM.Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Transplantation Conditioning: Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.Randomized Controlled Trials as Topic: Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.Taxoids: A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.Radiation Injuries, Experimental: Experimentally produced harmful effects of ionizing or non-ionizing RADIATION in CHORDATA animals.Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.Mucous Membrane: An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa.Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.Serotonin 5-HT3 Receptor Agonists: Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT3 RECEPTORS.Zinc Sulfate: A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Pain Measurement: Scales, questionnaires, tests, and other methods used to assess pain severity and duration in patients or experimental animals to aid in diagnosis, therapy, and physiological studies.Random Allocation: A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects.
Study 980231 (Randomized, double-blind, placebo-controlled). Three dose regimens were included: "pre-post", "pre", and placebo ... they usually get severe oral mucositis. Palifermin reduces the incidence and duration of severe oral mucositis by protecting ... Efficacy was demonstrated in the drug versus the placebo. Study 2000162 (Randomized, double-blind, placebo-controlled). ... Palifermin is also being studied in the prevention and treatment of oral mucositis and dysphagia (difficulty swallowing) in ...
... adverse events which occurred more often with sunitinib than placebo included diarrhea, anorexia, skin discoloration, mucositis ... of placebo patients (P=.006). Another 58% of sunitinib patients had disease stabilization vs. 48% of patients receiving placebo ... of patients who received placebo. Serious adverse events were reported in 20% of sunitinib patients and 5% of placebo patients ... At that time, patients receiving placebo were offered to switch over to sunitinib. In the primary endpoint of this study, ...
Clinical trial number NCT02324335 for "Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in ... who are receiving chemoradiation for head and neck cancer are randomized to receive either brilacidin-OM or the placebo three ... An active clinical trial, brilacidin for oral mucositis is detailed below. In pre-clinical research, a mouthwash formulation of ... Efficacy of Brilacidin Oral Rinse in Patients With Head and Neck Cancer The brilacidin trial for oral mucositis (Briladidin-OM ...
... for oral mucositis) (sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008) StemGen (Ancestim) (for use in ... reported positive results for brodalumab in a phase III trial comparing the compound with ustekinumab and a placebo in treating ... "are effective treatments compared with placebo for RA patients who are not well controlled by conventional DMARDs, improving ...
Oberoi, Sapna (2014-01-01). "Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta- ... placebo-controlled clinical trial". Lasers in Medical Science 28 (3): 743-753. doi:10.1007/s10103-012-1129-9. ISSN 1435-604X. ...
Diarrhea Oral mucositis (mouth, throat, or lip sores). Oral ulcers can be mitigated by proper oral hygiene, including rinsing ... "Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in ...
Oral mucositis consists of inflammation of the mouth, along with sores and ulcers in the tissues. Healthy individuals normally ... was given a placebo for two months followed by a two-month treatment of ALA. The results reported show that 91% of the group ... Chemotherapy often induces damage to the oral cavity, resulting in oral mucositis, oral infection, and salivary gland ... fifty patients suffering from idiopathic dysgeusia were given either zinc or a lactose placebo. The patients prescribed the ...
... and oral mucositis. LLLT has been studied as a treatment for hair loss; a review in 2012 found little evidence to support the ... the hair grew back faster on mice he treated compared with the placebos. He published those results in 1967. He went on to show ... but in most cases no better than placebo, in relieving short-term pain for rheumatoid arthritis, osteoarthritis, acute and ... "Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis". PLOS ONE. 9 (9): ...
One trail (Kerr 2010) assessed their effectiveness against a placebo disk. Strangely, patients from both groups (placebo and ... Mouth soreness and oral mucositis. Lipstick or food may stick to the teeth. A need to sip drinks frequently while talking or ... overall there is no strong evidence showing that Mucin Spray is more effective than a placebo in reducing the symptoms of dry ... it showed that Mucin Lozenges were ineffective when compared to a placebo. Mucoadhesive Disk: These disks are stuck to the ...
For example, it is possible through psychosurgery and some drug treatments, or by suggestion (as in hypnosis and placebo), to ... mucositis, joint pain, muscle pain, and abdominal pain due to diarrhea or constipation; hormone therapy, which sometimes causes ...
Other sources attribute the benefit to a simple placebo effect. Sanguinarine-containing mouthwashes are marketed as anti-plaque ... are used prior to and after oral surgery procedures such as tooth extraction or to treat the pain associated with mucositis ... Water Mouthrinse as Compared to Chlorhexidine and Placebo Rinses". Journal of Periodontology. 63 (1): 39-43. doi:10.1902/jop. ... that saline solution is just as effective as magic mouthwash in pain relief or shortening of healing time of oral mucositis ...
Burtness B, Goldwasser M, Flood W, Mattar B, Forastiere A (2005). "Phase III randomized trial of cisplatin plus placebo ... Eating problems Pain associated with lesions Mucositis Nephrotoxicity and ototoxicity Xerostomia Gastroesophageal reflux ...
Peri-Implant Mucositis. Peri-Implantitis. Peri-Implant Soft and Hard Tissue Deficiencies. [17] ... a pilot double blind randomized placebo-controlled clinical trial". BMC Oral Health. 16 (1): 57. doi:10.1186/s12903-016-0214-z ...
One trial (Kerr 2010) assessed their effectiveness against a placebo disk. Strangely, patients from both groups (placebo and ... Mouth soreness and oral mucositis.[1][3]. *Lipstick or food may stick to the teeth.[1] ... overall there is no strong evidence showing that Mucin Spray is more effective than a placebo in reducing the symptoms of dry ... it showed that Mucin Lozenges were ineffective when compared to a placebo.[8] ...
Effect of Prophylactic Low Level Laser Therapy on Oral Mucositis: A Systematic Review and Meta-Analysis. . Biblioteca virtual ... LLLT also reduced the following outcomes when compared to placebo-no therapy: severe mucositis at the time of anticipated ... overall mean grade of mucositis standardized mean difference −1.49, 95% CI −2.02 to −0.95, duration of severe mucositis ... was to determine whether prophylactic low level laser therapy LLLT reduces the risk of severe mucositis as compared to placebo ...
Treating radiodermatitis with LLLT is based on previously demonstrated decreased severity and duration of oral mucositis.32-34 ... a systematic review of possible mechanisms of action and clinical effects in randomized placebo-controlled trials. Photomed ... Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg. 2015;33( ... Clarkson JE, Worthington HV, Furness S, McCabe M, Khalid T, Meyer S. Interventions for treating oral mucositis for patients ...
Low-level laser for prevention and therapy of oral mucositis induced by chemotherapy or radiotherapy. Curr Opin Oncol. 2005;17( ... A systematic review and metaanalysis of randomised placebo-controlled trials. BMC Musculoskelet Disord. 2007;8:51.. 9. Hsieh ST ... However, a placebo-controlled, randomized, double-blind, multi-centered clinical investigation is warranted in order to ... Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in ...
PubMed journal article Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients ... TY - JOUR T1 - Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving ... Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. ... Randomized Clinical Trial of Chlorhexidine Versus Placebo for Prevention of Oral Mucositis in Patients Receiving Chemotherapy. ...
... oral hygiene program using water as a mouth rinse is cost efficient and may be effective in preventing oral mucositis. ... Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy ... Design: Randomized, double-blind, placebo-controlled, clinical trial. Settings: 23 outpatient clinics and office practices in ... Interestingly, the PSMA program appeared to reduce the incidence of mucositis from on a prior estimate of 44% to less than 26 ...
... a placebo-controlled double-blind randomized stud were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad. ... PubMed journal article Sucralfate mouth washing in the prevention of radiation-induced mucositis: ... Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled ... Makkonen TA et al: "Sucralfate mouth washing in the prevention of radiation-induced mucositis: a placebo-controlled double- ...
... placebo-controlled trial. - Michelle Nottage, Sue-Anne McLachlan, Mary-Anne Brittain, Amit Oza, David Hedley, Ronald Feld, ... Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, ... and the placebo-treated group. Some mucositis was reported by 79% of the patient group. Assessment of mucositis by trial staff ... Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. ...
... of oral mucositis (painful sores in the mouth). Mucositis is a common side effect for patients receiving chemotherapy (cancer- ... Type: Placebo Comparator Description: Participants received a single IV dose of placebo three days before the start of ... of oral mucositis (painful sores in the mouth). Mucositis is a common side effect for patients receiving chemotherapy (cancer- ... The acute oral mucositis (OM) evaluation phase includes the time from randomization to the time of severe OM (WHO Grade 3 or 4 ...
Placebo Comparator: Placebo Intervention: Drug: Placebo. Publications * Not Provided. * Includes publications given by the data ... The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients. The safety and ... The purpose of this Study is to evaluate the efficacy and safety of rhEGF on oral mucositis in patients receiving the radiation ... The purpose of this Study is to evaluate the efficacy and safety of rhEGF on oral mucositis in patients receiving the radiation ...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to ... A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer. The safety ... Oral Mucositis. Superoxide Dismutase Mimetic. Cisplatin. Intensity-Modulated Radiation Therapy. Chemoradiation. OM. IMRT. Head ... Mucositis. Stomatitis. Neoplasms by Site. Neoplasms. Gastroenteritis. Gastrointestinal Diseases. Digestive System Diseases. ...
Placebo Comparator: Placebo toothpaste Fluoride toothpaste will be used by filling the individual silicone stent allowing it to ... Triclosan Toothpaste as a Preventive Strategy of Mucositis in Smokers. The safety and scientific validity of this study is the ... Triclosan Toothpaste as a Preventive Strategy of Mucositis in Smokers Official Title ICMJE Effect of a Triclosan-containing ... Other: Placebo toothpaste During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, ...
Placebo Comparator: Placebo Patients are randomized 1:1 active/placebo.. Drug: Placebo Placebo is 0.9% sodium chloride (normal ... Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Oral Mucositis Drug: SGX942 Drug: Placebo Phase 3 ... To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis (SOM; defined as World ... To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving ...
31% in the placebo group; PÂ = 0.007) and altered taste. Seven of the 8 patients who had severe mucositis in the placebo group ... In the placebo cycle, the median duration of grade 3 or 4 mucositis was 6 days (range, 3 to 12 days) and the median duration of ... Compared with placebo, palifermin reduced the cumulative incidence of moderate to severe (grade 2 or higher) mucositis (44% vs ... Eight of 16 patients (50%) in the placebo group had grade 3 or 4 mucositis. Of these, 7 received open-label palifermin in the ...
The purpose of this study is to evaluate the efficacy and effect of palifermin on the incidence of oral mucositis in subjec... ... and skeletal-related events compared with placebo... ... Palifermin Pre only, placebo, Palifermin Pre and Post. Status. ... Home » Topics » Multiple Myeloma » Research » A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With ... The purpose of this study is to evaluate the efficacy and effect of palifermin on the incidence of oral mucositis in subjects ...
Helping you find trustworthy answers on Oral Mucositis , Latest evidence made easy ... Find all the evidence you need on Oral Mucositis via the Trip Database. ... Randomized double-blind, placebo-controlled trial evaluating oral glutamine on radiation-induced oral mucositis and dermatitis ... 2. Oral mucositis Oral mucositis Oral mucositis - Symptoms, diagnosis and treatment , BMJ Best Practice Youll need a ...
... placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Br J ... A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis. Support Care Cancer. 2014 Mar;22: ... Hinchazón (inflamación) y ampollas dentro de la boca (mucositis oral). El enjuague en la boca y luego otro enjuague con miel ... Hinchazón (inflamación) y ampollas dentro de la boca (mucositis oral): Se usó 20 mL de miel para enjuagar la boca 15 minutos ...
... placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Br J ... A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis. Support Care Cancer. 2014 Mar;22: ... For swelling (inflammation) and sores inside the mouth (oral mucositis): Up to 15 grams of honey has been applied inside the ... For swelling (inflammation) and sores inside the mouth (oral mucositis): Honey 20 mL has been rinsed around the mouth 15 ...
To evaluate the preliminary efficacy of palifermin in reducing the incidence and severity of oral mucositis (OM) in patients w ... Grade 4: mucositis to extent alimentation not possible.. Outcome Time Frame:. Within 6 blinded cycles (3-week cycles), up to 18 ... the last dose of study drug (either palifermin or placebo) was given.. At your end of study visit, you will be evaluated for ... This will be done for 18 weeks (a total of 12 injections). A placebo is a. substance that looks like the study drug, but which ...
... placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus.(Report) by Phytomedicine: International ... We developed this scale by modifying the oral mucositis index, which has been validated for use in measuring oral mucositis ... none on placebo, one on curcuminoids), dry mouth (two on placebo, one on curcuminoids), and metallic taste (one on placebo, ... "Other" side effects reported by study subjects included: headache (five on placebo, one on curcuminoids), rash (one on placebo ...
RATIONALE: Acupuncture may be effective in relieving mucositis-related pain caused by chemotherapy in patients undergoing stem ... A Randomized, Placebo-Controlled, Blinded Study Of Acupuncture Therapy In Mucositis-Related Pain In Patients Undergoing ... A Randomized, Placebo-Controlled, Blinded Study Of Acupuncture Therapy In Mucositis-Related Pain In Patients Undergoing ... Compare the efficacy of acupuncture vs placebo acupuncture in alleviating. mucositis-related pain secondary to high-dose ...
... the results were not deemed clinically different when compared with placebo. ... Use of two medicated mouthwashes reduced pain from oral mucositis during the first four hours after administration; however, ... was more effective than placebo (92 patients) in reducing oral mucositis pain for patients undergoing radiotherapy to the oral ... antacid mouthwash compared with placebo significantly reduced oral mucositis pain during the first four hours after ...
Cellceutix Reports Very Encouraging Interim Analysis Of Phase 2 Drug Candidate Brilacidin For Severe Oral Mucositis (OM) In ... Placebo): 7 of 10 patients (70 percent) ... Cellceutix: A New Standard Of Care In Oral Mucositis In The ... Cellceutix CEO Discusses Brilacidin Following Interim Trial Results For Treating Oral Mucositis And Inflammatory Bowel Disease ... Cellceutix To Present At Biotech Showcase 2017; Brilacidin For Oral Mucositis Nears Interim Results. ...
Randomized double-blind placebo-controlled trial of propolis for oral mucositis in patients receiving chemotherapy for head and ... Vynograd N, Vynograd I, Sosnowski Z. A comparative multi-centre study of the efficacy of propolis, acyclovir and placebo in the ... Propolis is also used topically as a mouth rinse to treat painful mouth sores and inflammation (oral mucositis) and thrush ( ... Propolis allergy: a cause of oral mucositis with ulceration. Oral Surg Oral Med Oral Pathol 1990;70:584-6. View abstract. ...
... the proportion of patients who get through stomatotoxic chemotherapy without developing ulcerative oral mucositis. An error in ... The study was powered to detect an increase in patients free of mucositis from 36% expected with placebo to 55% with iseganan. ... Bradford reported that the proportion of patients free of mucositis on day 21 was 33% with placebo vs 43% with iseganan. He ... iseganan reduced the average oral mucositis severity as defined by mean Oral Mucositis Assessment Scale (OMAS) score by 22% (P ...
Randomized, double blind, placebo-controlled, phase I/II study. Measurement Instruments/Methods: * NCI-CTC mucositis toxicity ... 2004). Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in ... Assessments before HSCT regimen, day of transplant, and 3x/wk until mucositis resolved.. ...
  • A rigorous, intention-to-treat efficacy analysis that included the improperly treated patients still showed that iseganan significantly decreased mouth pain and stomatitis compared to placebo, and that the increase in the proportion of patients without ulcerative mucositis approached statistical significance ( P = 0.067). (cancernetwork.com)
  • We also suggest KGF may be offered to children receiving HSCT conditioning with regimens associated with a high rate of severe mucositis. (bmj.com)
  • The authors of the study concluded: "According to the findings in this study, omega-3 fatty acids in oral form have a significant effect on wound healing induced by oral mucositis. (naturalnews.com)
  • COMMENTING ON the results of this trial of GC4419, Rajesh V. Lalla, DDS, PhD, President of the Multinational Association of Supportive Care in Cancer, said, "This study demonstrated this agent's strong potential for the management of oral mucositis in patients receiving head and neck radiation. (ascopost.com)
  • Patients were issued drug bottles containing a 5-day supply of either placebo or iseganan. (cancernetwork.com)
  • Patients (N = 66) were randomly assigned to receive either placebo or IM (4 mg/day for 14 consecutive days). (ovid.com)
  • Study subjects were randomized to receive either placebo or curcuminoids at 2000 mg/day for 7 weeks. (thefreelibrary.com)
  • Each cohort will receive either placebo, SCV-07 at a dose of 0.02 mg/kg, or SCV-07 at a dose of 0.10 mg/kg. (marketwired.com)
  • Patients enrolled in the trial were randomized to receive a single infusion of either placebo or one of three dose levels of velafermin (10 mcg/kg, 30 mcg/kg or 60 mcg/kg) administered 24 hours after BMT. (bio-medicine.org)
  • Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI]. (rochester.edu)
  • Currently, the most prescribed treatment for inflammation secondary to mucositis relies on the use of corticosteroids in the oral, injection and topical forms as well as orally administered NSAIDs. (scirp.org)
  • While the etiology and the pathogenic mechanisms of OM have not been fully elucidated yet, several studies have reported a major role of DNA damage and reactive oxygen species (ROS) during the early phases of oral and intestinal mucositis [ 4 - 7 ]. (hindawi.com)
  • Palifermin (180 µg per kg of body weight) or placebo was administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles). (annals.org)
  • Total pain reduction during the four hours after a single dose of the mouthwashes compared with placebo served as the primary endpoint, with a minimal clinically important difference being a 3.5-point change. (curetoday.com)
  • The mouth-rinse with G-CSF at a dose of 150-300ug plus 100ml-500ml normal saline was started from the time of oral mucositis was confirmed and continuously used for at least 7 days as one course. (koreascience.or.kr)
  • The primary efficacy endpoint was a Kaplan-Meier estimate of the proportion of patients not developing ulcerative oral mucositis through study day 21. (cancernetwork.com)
  • The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. (rochester.edu)
  • Preclinical efficacy and safety has been demonstrated in numerous animal disease models including mucositis, colitis, melioidosis, macrophage activation syndrome (MAS) and other bacterial infections. (biospace.com)